Fig. 1: SRC-3 level correlates with treatment outcomes of MM patients in clinic. | Nature Communications

Fig. 1: SRC-3 level correlates with treatment outcomes of MM patients in clinic.

From: Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma

Fig. 1: SRC-3 level correlates with treatment outcomes of MM patients in clinic.The alternative text for this image may have been generated using AI.

a Histological views of bone disruption, percentage of plasma cells (n = 3 biological independent samples), and SRC-3 (NCOA3 as gene nomenclature) expressions (mean ± SD, n = 3 biologically independent experiments) in bone marrow biopsies from patients with CR or RR before (pre-T) and after (post-T) bortezomib (BTZ) based treatments. MRI, magnetic resonance imaging; CT, computerized tomography. All P values were determined by two-sided Student’s t test. b NCOA3 expressions in plasma cells from healthy controls (PC, n = 26), newly diagnosed MM patients (NDMM, n = 35), and refractory or relapse MM patients (RRMM, n = 30). Two-sided P values were determined by Student’s t test; mean ± SD. c NCOA3 expression in newly diagnosed MM patients without known mutations (non-M, n = 67), with t(4;14) (n = 43) and other cytogenetic abnormalities (including t(11;14), t(16;14), and 1q21; n = 22). Two-sided P values were determined by Student’s t test; mean ± SD. d NCOA3 expression in patients with complete response (CR, n = 12) and patients with refractory or relapse (RR, n = 12) before (pre-T) and after treatment (post-T), and (e) shows the difference of NCOA3 expression in the two groups. Purple color, t(4;14)+. Two-sided P value was determined by Student’s t test; mean ± s.d. from n = 3 independent experiments. f The correlation coefficient between the NCOA3 expression and numbers of bone lesion in MM patients (n = 3 independent experiments from n = 19 samples); x2 = 0.5806; P < 0.0001. g Immunohistochemical images of bone marrow biopsies from two patients with disease progression before (pre-T) and after treatment (post-T). Scale bar, 200 μm. h Correlation of NCOA3 expression with progression-free survival (PFS) and overall survival (OS) in patients after receiving bortezomib (BTZ)-based treatment regimens in our cohort (n = 64). All P-values were determined by Pearson Coefficient and Log-ranks test. Source data are provided as a Source Data file.

Back to article page